Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey
Saved in:
| Title: | Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey |
|---|---|
| Authors: | Tina Bhutani, Sayeli Jayade, Sanika Rege, Hannah Penton, Vardhaman Patel, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Lauren Seigel |
| Source: | Journal of Dermatological Treatment, Vol 35, Iss 1 (2024) |
| Publisher Information: | Taylor & Francis Group, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Dermatology |
| Subject Terms: | Cross-sectional survey, humanistic burden, psoriasis therapy, Dermatology, RL1-803 |
| Description: | Purpose: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. Materials and Methods: Residual disease was defined as experiencing moderate, severe, or very severe psoriasis over the past week or having ≥3% body surface area affected, despite treatment. Factors associated with residual disease and its effects on flare-ups, humanistic burden, and health care resource utilization (HCRU) were evaluated. Results: Of the 344 apremilast users (mean age, 44.9 years; female, 65.4%), 174 (50.6%) had residual disease. It was more prevalent in Black versus White participants (OR, 4.5; 95% CI, 1.6–12.2), those receiving apremilast for ≥1 versus |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1471-1753 0954-6634 |
| Relation: | https://doaj.org/toc/0954-6634; https://doaj.org/toc/1471-1753 |
| DOI: | 10.1080/09546634.2024.2366532 |
| Access URL: | https://doaj.org/article/6a541e87403a42e39eeb760a48781c7a |
| Accession Number: | edsdoj.6a541e87403a42e39eeb760a48781c7a |
| Database: | Directory of Open Access Journals |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Purpose: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. Materials and Methods: Residual disease was defined as experiencing moderate, severe, or very severe psoriasis over the past week or having ≥3% body surface area affected, despite treatment. Factors associated with residual disease and its effects on flare-ups, humanistic burden, and health care resource utilization (HCRU) were evaluated. Results: Of the 344 apremilast users (mean age, 44.9 years; female, 65.4%), 174 (50.6%) had residual disease. It was more prevalent in Black versus White participants (OR, 4.5; 95% CI, 1.6–12.2), those receiving apremilast for ≥1 versus |
|---|---|
| ISSN: | 14711753 09546634 |
| DOI: | 10.1080/09546634.2024.2366532 |